Rigel PharmaceuticalsFRA:RI2 +0.89%76 Interest Coverage is 8.29 as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €23.38. The stock has 7 warning signs investors should review. Among 377 Biotechnology companies, Rigel Pharmaceuticals ranks worse than 68.97% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Rigel Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was €10.3 Mil. Rigel Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was €-1.2 Mil.
Rigel Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 8.29.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Rigel Pharmaceuticals's Interest Coverage or its related term are showing as below:
FRA:RI2'
s Interest Coverage Range Over the Past 10 Years
Min: 3.06 Med: No Debt Max: No Debt
Current: 18.05
FRA:RI2's Interest Coverage is ranked worse than 68.97% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs FRA:RI2: 18.05
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Rigel Pharmaceuticals Interest Coverage Related Terms
Rigel Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:RI2 vs CBIO, TRAX, GYRE: Interest Coverage Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Interest Coverage of 8.29 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Rigel Pharmaceuticals and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Rigel Pharmaceuticals' Interest Coverage has ranged from 3.06 to 10,000.00. According to the industry distribution chart, Rigel Pharmaceuticals ranks #260 out of 377 companies in the Biotechnology industry, placing it in the top 69%.
Is Rigel Pharmaceuticals' Interest Coverage too high?
Rigel Pharmaceuticals' current Interest Coverage of 8.29 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. Rigel Pharmaceuticals' value of 8.29 is 92.2% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #260 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Interest Coverage compare to CBIO and TRAX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #260 out of 377 companies for Interest Coverage. This places Rigel Pharmaceuticals in the lower half of its industry. The industry median Interest Coverage is 106.07. Rigel Pharmaceuticals' value of 8.29 is 92.2% below this benchmark. Historically, Rigel Pharmaceuticals' own Interest Coverage has ranged from 3.06 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 106.07, Rigel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Interest Coverage of 8.29 is 92.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Interest Coverage is 8.29, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Interest Coverage of 8.29. The stock's GF Value™ is €23.38, compared to a current price of €31.86 — trading 36.3% above its estimated fair value. The current Interest Coverage is 8.29, which is 100% below median its 10-year median of 10,000.00 and 92.2% below the Biotechnology industry median of 106.07. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Interest Coverage is 8.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €31.86 is trading 36.3% above its estimated GF Value™ of €23.38.
Key valuation signals for FRA:RI2:
Interest Coverage: 8.29 (100% below median its 10-year median of 10,000.00)
GF Value™: €23.38 vs. price of €31.86 (36.3% above fair value)
Industry Position: 92.2% below the Biotechnology median (#260 of 377)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score
Get the complete analysis for FRA:RI2
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
